Why does Ozempic make you feel full after just a few bites? Ozempic® (semaglutide) is a GLP-1 receptor agonist that can affect several of the body's signals involved in hunger, appetite, and fullness. But is the feeling of fullness simply because food stays in your stomach longer? Not exactly. In this Rehealthify Short, we explain what may be happening inside your body when semaglutide makes you feel full sooner—including: • How semaglutide mimics GLP-1 signaling • How GLP-1 is involved in hunger and satiety • Why you may feel satisfied after eating less • How the brain and digestive system work together to regulate appetite • How semaglutide can affect gastric emptying • Why “feeling full” isn't necessarily the same as having a stomach that stays full • Why the effects can vary from person to person Research suggests that GLP-1 receptor agonists can reduce hunger and increase feelings of fullness and satiety. Semaglutide can also affect gastric emptying, although the magnitude and persistence of this effect can vary depending on the medication, dose, duration of treatment, and individual response. The FDA prescribing information for Ozempic also states that Ozempic delays gastric emptying and lists gastrointestinal effects such as nausea, vomiting, diarrhea, abdominal pain, and constipation among its most common adverse reactions. **Want to understand what your medications are actually doing inside your body?** Subscribe to **Rehealthify** for clear, science-based explanations of diabetes, medications, metabolism, and the human body—without the confusing medical jargon. **IMPORTANT HEALTH INFORMATION:** This video is for general educational and informational purposes only. It is not medical advice, diagnosis, or treatment and should not be used as a substitute for advice from a qualified healthcare professional. Individual responses to medications can vary. Do not start, stop, change, or adjust any medication based solely on information in this video. If you have questions or concerns about Ozempic (semaglutide), including side effects or how it may affect you, speak with your healthcare provider or pharmacist. Ozempic® is a registered trademark of Novo Nordisk A/S. Rehealthify is not affiliated with or endorsed by Novo Nordisk. ### References 1. U.S. Food and Drug Administration (FDA). **Ozempic (semaglutide) Prescribing Information.** Revised January 2025. 2. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. **The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.** *Diabetes, Obesity and Metabolism.* 2021;23(3):754–762. 3. Aldawsari M, et al. **The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials.** *Diabetes, Metabolic Syndrome and Obesity.* 2023;16:575–595. 4. Rutigliani G, et al. **GLP-1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms.** *Obesity Reviews.* 2026. #ozempic #semaglutide #glp1 #type2diabetes #diabetes #diabetesmedication #glp1medications #bloodsugar #appetitesuppression #satiety #weightloss #health #healthfacts #medicaleducation #rehealthify #youtubeshorts #shorts